Connect with us

Fintech PR

Major Upgrade to Auto-Invest Bot: Portfolio Set to Begin a New Chapter




Bitget Markets Guide

SINGAPORE, Sept. 14, 2023 /PRNewswire/ — Recently, the Bitget team upgraded the auto-invest bot and introduced a brand new Portfolio mode. Bitget adheres to the principle of “Trade smarter”, aiming to create a more convenient, efficient, and intelligent trading environment for users. Helping users to make smarter and more professional investments or trading decisions, which offers them the potential for greater profit.

1. What is Portfolio?

Portfolios are smart recommendations that can be found in Bitget’s auto-invest bot section. Portfolios are composed of a variety of leading tokens in a particular domain or sector, each with a specified weight. The weight proportion of a token represents its importance within the portfolio or within that particular sector. Projects are generally evaluated and ranked comprehensively on a number of dimensions, including growth prospects, technology, popularity, and innovation. Bitget is committed to recommending the highest-quality investment portfolios to users.

Portfolios combine different assets within a particular domain or sector, and instead of investing in a single coin, users are investing in an entire sector or multiple domains. Portfolios achieve investment diversification while effectively mitigating the risk associated with individual positions, helping users guard against and balance significant market fluctuations. For example, if you want to generate stable high returns in the crypto market, you can buy several different tokens so that you have a diversified portfolio. If some of the tokens experience major fluctuations or other issues, your entire Portfolio will not be greatly affected, as the performance of other tokens will offset your overall losses.

Understanding and using a Portfolio is of utmost importance for the average user who is seeking gains in the ever-changing crypto market. However, with the constant proliferation of various projects, trading has become more challenging, and the complexity of distinguishing between projects has also increased. Only by continuously improving one’s comprehensive capabilities can you select high-quality projects and build top-notch portfolios. Recognizing this market phenomenon, Bitget has launched a user-friendly smart Portfolio mode to help users navigate the crypto market with ease.

2. Characteristics of Bitget Portfolios

  • More Professional: The coins and their weight proportions in the Portfolio are carefully assessed and rigorously selected through a comprehensive evaluation, strict screening, and historical data analysis by Bitget’s team.
  • Simple Settings, Intuitive Activation: Users can select their favorite Portfolio based on returns and the number of users, and by simply filling in the investment amount, they can initiate the auto-invest portfolio with a single click.
  • Diversified Risk Appetites: Users have different risk appetites, and Bitget offers Portfolios with different risk levels to cater to users with different risk profiles. They are categorized into three main types: low risk, medium risk, and high risk, with investment returns ranging from low to high depending on the risk level. Whether you are a conservative user or an aggressive user, you can find the right Portfolio for you.
  • Comprehensiveness and Richness: Portfolio recommendations encompass a collection of assets from a single or multiple domains, providing users with diversified choices. Bitget will continue to introduce more bots in response to market fluctuations.

3. Portfolio Recommendation

The core of a high-quality Portfolio lies in the correlation and risk between each asset within the Portfolio, rather than just a simple combination of different assets.

3.1 Selection of Investment Targets

In the ever-changing crypto market, selecting the right investment targets is not an easy task, but there is a solution to every challenge. Users can perform an initial screening in the following two ways.

  • Relying on market capitalization

The larger the market capitalization, the relatively safer the tokens.

The larger the market capitalization, the better the liquidity.

  • Selecting leading projects within a sector

For average users, it is advisable to refrain from investing in seemingly bullish but unfamiliar projects, since we can not anticipate the hidden factors

behind the sudden surge of the project, which may lead to unnecessary losses. Choosing the leading project within a particular sector is the simplest and safest approach. The coming years will continue to be an era of competition for existing resources, which applies to various sectors, with high-quality resources tending to favor leading projects. Leading projects typically outshine other unknown ones in terms of brand advantage, market channels, cost advantages, R&D capabilities, and talent resources. The strong will continue to grow stronger, while the weak will find it increasingly harder to survive.

3.2 Asset Allocation

Asset allocation is a critical concept in Portfolio theory, referring to how assets are allocated based on their characteristics, such as risk, return, liquidity, and more. The purpose of asset allocation is to achieve investment targets while minimizing risk.

Typically, different types of assets carry varying risks and rewards, so asset allocation requires considering these factors comprehensively to achieve optimal investment returns and risk control.

3.3 Diversified Investment

Diversified investment is a key concept in Portfolio theory, which refers to spreading assets across different tokens or sectors, reducing the investment weight of a single token or sector to mitigate overall risk. This is because a single token or a particular sector is typically influenced by various economic and market factors. If users allocate all their assets to the same token or sector, in the event of a significant impact on that token or sector, their entire investment may incur irreparable losses.

It is important to note that Portfolio theory does not guarantee a return on investment, as markets involve uncertainty and risks. However, through proper asset allocation and Portfolio management, you can enhance risk control and get the best possible return on your investment. At the same time, regularly evaluating and adjusting your Portfolio ensures that your investment strategy is always in line with your investment targets and risk appetite.

4. How to Create a Portfolio strategy?  (Web)

4.1 Log in to your Bitget account. Head to Homepage > Bots, and click on Spot Auto-invest to trade.

4.2 Head to Recommended Portfolio, and select the corresponding recommended card based on the Portfolio profile information and ROI. Click on Select to view the specific cryptocurrency composition and the corresponding weight proportions. (Recommended Portfolio mode is more suitable for novice users)

Friendly reminder:

4.3 If you are an experienced trader, you can use Manual mode to periodically adjust your Portfolio based on market conditions and investment targets. For example, if an asset is performing well, you might consider increasing its weight; if an asset is not performing well, you might consider decreasing its weight or cutting its holdings.

4.4 Select the investment frequency. The investment intervals can be hourly or monthly. The calculation will be based on the local time of your current device. All asset prices will reflect the market price at the time of your selection.

4.5 Enter the amount, which is the total value you want to invest (currently in USDT). Ensure that your spot account has a sufficient balance. Otherwise, the bot may be forced to terminate suddenly. You can still adjust the amount after the bot has been activated.

4.6 Check the box below if you want the bot to be automatically terminated when your spot account balance is insufficient. You can reactivate the bot at any time.

Note: To learn more about the relevant parameters, view Spot auto-invest parameters explained.

4.7 View bot performance

Go to the bottom of the Trading bots page to see your current bots. You can also view the Bot Details or choose Terminate.

5.  Crypto price Today

How can I predict cryptocurrency prices?

What are the top crypto coins right now?

What drives cryptocurrency prices?

How to read cryptocurrency prices?

Come to Bitget Crypto Price, you can see more than 12,000 crypto real-time prices, Watchlist, All crypto
TrendingATH, 52 weeks high and 52 weeks low

6.   Crypto Calculator

Bitget real-time crypto calculator assists you in converting prices online between two currencies. Stay updated on popular cryptocurrency exchange rates like Bitcoin, Ethereum, Cardano, Solana, and Dogecoin with the latest conversion rates.

Keep track of the latest news and pricing by signing up with Bitget today. Check out our guides that cover how to convert and buy crypto, including How to buy Bitcoin and How to buy Ethereum.


Portfolio is a trading tool. The abovementioned information should not be regarded as financial or investment advice provided by Bitget. Portfolio returns may be impacted by one-sided market conditions or improper price interval settings. You can adjust your Portfolio strategy according to market conditions. Your use of this tool is subject to your unconditional acceptance of all the Terms and Conditions of Bitget. You should be fully aware of the risks associated with cryptocurrency investments and proceed with caution. You agree that all investments conducted on reflect your genuine investment intent, and you unconditionally accept the potential risks and gains of your investment decisions.

Photo –

Cision View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

The Office of the Executive Committee of the WMC Released the List of “Top 500 Chinese Manufacturing Enterprises in 2023”




HEFEI, China, Sept. 22, 2023 /PRNewswire/ — The 2023 World Manufacturing Convention (WMC) was opened on September 20 in Hefei, Anhui Province, China. In the convention, the list of “Top 500 Chinese Manufacturing Enterprises in 2023” was released, indicating that the operating revenue of China’s top 500 manufacturing enterprises in 2023 has exceeded 50 trillion RMB for the first time, reaching 51.06 trillion RMB, which was an increase of 8.38%.

Among the top 500 manufacturing enterprises, the heavy chemical industry still occupies the main position, and four out of the five industries with the largest operating revenue belong to the heavy chemical industries. Meanwhile, the pace of development of strategic emerging industries has accelerated, and most of the enterprises with the top operating revenue and net profit growth are strategic emerging industry enterprises. The top five industry’s average revenue growth rates are from power batteries and energy storage batteries, wind energy, solar equipment manufacturing, medical equipment manufacturing, computer and office equipment and chemical fiber manufacturing, of which the top three growth rate reached more than 45%, respectively 59.72%, 49.42%, 45.54%. According to the analysis of the ranking, the total R&D expenses of China’s top 500 manufacturing enterprises in 2023 have reached 109.6215 billion RMB, which was an increase of 3.83% over the previous year; the R&D intensity was 2.33%, which is at a high level in recent years. The average R&D expenses of industries such as aerospace, communication equipment manufacturing, railway traffic equipment manufacturing, textile printing and dyeing are at the forefront from the perspective of various industries.

The “2023 Development Report on Anhui Manufacturing” prepared by the Anhui Provincial Department of Economy and Information Technology was also released on the day of the convention. The report shows that the average annual growth rate of industrial value added of enterprises above the designated size in Anhui Province was 9.5% from 2012 to 2022, ranking the first in the central region, the first in the Yangtze River Delta and the fourth in whole China. In 2022, the province’s industrial enterprises above the designated size have achieved an operating revenue of 4.9 trillion RMB, ranking 10th in the country. Among them, manufacturing enterprises above the designated size have achieved an operating revenue of 4.4 trillion RMB; the added value of the manufacturing industry has exceeded 1 trillion RMB, accounting for 26.5% of GDP, which was an increase of 0.3 percentage points over the previous year.

In recent years, Anhui’s manufacturing industry has accelerated the development of integrated clustering, especially the clustering of advanced manufacturing chains, forming an unformidable trend. The top one industry is “automobile” with irresistible force, while the PV and energy storage gathering “sparkling light” into a raging torch, the IC industry showing its brilliant “core”, the new “displays and screens” experiencing a rapid boom, and the AI “valley” astonishing the world. A number of industrial landmarks have become an important force leading the trend of China’s and even the world’s manufacturing industry.

Contact: Yuan Fan
Tel: 0086- 13552640063
E-mail: [email protected] 

Photo –
Logo –

World Manufacturing Convention Logo

Cision View original content:

Continue Reading

Fintech PR

Asian International Arbitration Centre and SOAS University of London, Arbitration and Dispute Resolution Centre sign MoU to promote best practice in arbitration




LONDON, Sept. 22, 2023 /PRNewswire/ — The Asian International Arbitration Centre (AIAC), Kuala Lumpur, and SOAS University of London, Arbitration and Dispute Resolution Centre (SADRC) have yesterday (Thursday 21 September) signed a Memorandum of Understanding to advance collaboration and promote best practice in alternative dispute resolution techniques, including arbitration.

The MoU will see the AIAC and SADRC further develop teaching and research activities in alternative dispute resolution in line with international best practice, to coordinate efforts to promote the use of alternative dispute resolution.

Azalina Othman Said, Malaysia’s Minister of Law and Institutional Reform, was in London to attend the MoU signing, and offer it Malaysia’s full support to increase dialogue in arbitration. The Minister attend the MoU signing alongside Malaysia’s High Commissioner to the UK Dato’ Zakri Jaafar, Solicitor General II of the Attorney General’s Chambers of Malaysia, Datuk Almalena Sharmila binti Dato’ Dr. Johan, and Deputy Director General of the Legal Affairs Division of the Prime Minister’s Department, Dr. Punitha Silivarajoo. The Head of Legal Services Trade and Promotion at the UK Ministry of Justice, Holly O’Callaghan, attended to offer the UK Government’s support.

Speaking about the MoU signing, Emilia Onyema, Professor of International Commercial law, SOAS & Director, SADRC, said:

“At the SADRC, we are proud that today we have become a partner of the Asian International Arbitration Centre. Through signing this MoU, we hope to promote alternative dispute resolution techniques in our SOAS regions, Asia, Middle East and Africa, and particularly Malaysia, and learn from our shared experiences.”

Sundra Rajoo, Director of AIAC, said:

 “We are delighted that today, the Asian International Arbitration Centre has formally agreed a MoU with SOAS University of London’s prestigious new Arbitration and Dispute Resolution Centre. The formalization of the MoU between both institutions is indeed a remarkable and significant achievement. We firmly believe that through this innovative partnership, we can enhance our joint efforts to promote best practices in alternative dispute resolution, benefiting not only the UK and Malaysia but also the broader Asian and African region.”

Azalina Othman Said, Malaysia’s Minister of Law and Institutional Reform, said:

”The UK and Malaysia have a long shared history of collaborating to tackle mutual challenges, and the signing of the MoU between the Asian International Arbitration Centre and SOAS University of London’s Arbitration and Dispute Resolution Centre underscores the depth of our relationship and our commitment to advancing global best practices in arbitration.”

In practical terms, this collaboration would include steps to encourage, enhance and promote the following areas of cooperation:

  • Joint courses and training;
  • Joint research programmes;
  • Contribution of expertise – such as researchers, panellists, speakers and guest lecturers – to initiatives which share common goals;
  • Publication of academic journals, books and newsletters;
  • Student internship programmes;
  • Organising or hosting joint conferences, workshops, seminars and forums.

In addition to arbitration, the two centres have committed to also promote Islamic arbitration, sports arbitration, mediation, adjudication, and domain name dispute resolution as alternative dispute resolution methods.

The MoU signing comes ahead of the inaugural London International Arbitration Colloquium, which will take place on Monday 25 September at the International Dispute Resolution Centre in London, to consider the role of international arbitration involving sovereign states.

Over the course of three panel sessions, guests will hear expert insights on jurisdictional challenges in investment arbitration, the impact of investment claims on states and their sovereignty, and the role of third-party funding in access to justice.


For more information, contact:



View original content:

Continue Reading

Fintech PR

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty




FN Media Group Presents USA News Group News Commentary

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ — USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer Moonshot” initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

At the 2023 ASCO Annual Meeting Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) shared exciting results from its important study, called BRACELET-1, with results that caught the eye of RBC Capital. The oral presentation shared at the event described how they’ve been testing a treatment for advanced breast cancer, and it’s looking very promising.

The treatment combines Oncolytics’ flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel. Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed. The results of BRACELET-1 showed that this mixture could slow down the cancer significantly. It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

For people battling cancer, this means more quality time before the cancer might get worse. Specifically, people getting the combined treatment had about 9.5 good months before the disease advanced, compared to just 6.3 months with only paclitaxel.

Moreover, the new treatment was better at shrinking or even eliminating the cancer. An impressive 37.5% of patients responded to the combined treatment, as opposed to just 13.3% with paclitaxel alone.

“BRACELET-1’s positive results complement prior phase 2 data showing a statistically significant increase in overall survival when pelareorep was combined with paclitaxel by demonstrating similar robust improvements in PFS and ORR in less heavily pre-treated patients,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “Given this exciting finding, our next step is to discuss our data with the FDA to investigate incorporating dual PFS and OS endpoints into our breast cancer program’s registrational study. Including a PFS endpoint will substantially reduce the time to a pivotal readout from the registrational trial, thereby accelerating pelareorep’s path to potential approval as we work to address the urgent needs of HR+/HER2- breast cancer patients.”  

Following these encouraging results, Oncolytics Biotech is now ready to take the next steps in advancing its breast cancer program. They’re planning to talk to the FDA and push forward with more registrational studies, having already received Fast Track Designation for pelareorep in the treatment of advanced/metastatic pancreatic cancer, in late 2022. This could make pelareorep an approved treatment for breast cancer sooner than expected.

Another highlight from the ASCO presentations was that of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Zymeworks Inc. (NASDAQ: ZYME). Together the two companies presented promising data from a pivotal Phase 2b trial, evaluating the bispecific antibody, zanidatamab, in HER2-amplified biliary tract cancers (BTC), a particularly aggressive group of cancers that currently lack HER2-targeted treatment options.

The results were not only presented at ASCO but also concurrently published in The Lancet Oncology. They demonstrated meaningful clinical benefit, including antitumor activity, a confirmed objective response rate (cORR) of 41.3%, a median duration of response (DOR) of 12.9 months, and a median progression-free survival (PFS) of 5.5 months.

“The HERIZON-BTC-01 trial advances an exciting field of oncology research where we can leverage next-generation sequencing on BTC patients to understand genomic markers of the disease and choose the appropriate targeted therapies for these patients,” said Shubham Pant, M.D., professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

The data clearly outshines current chemotherapy treatments for BTC, which offer only a 5 to 15 percent ORR and median PFS of 1.4 to 4 months. The Zymeworks-Jazz partnership showcased an oral presentation on the pivotal HERIZON-BTC-01 study results demonstrating zanidatamab’s meaningful clinical benefit and tolerable safety profile in patients with HER2-amplified BTC.

Zanidatamab has already been granted Breakthrough Therapy designation and two Fast Track designations by the FDA, making it an exciting contender in the fight against these tough-to-treat cancers. These exciting results suggest a potential future where targeted treatments like zanidatamab transform the lives of patients in critical need.

With three oral presentations and two poster discussions, and over 25 abstracts, Amgen’s (NASDAQ: AMGN) presence at ASCO included new scientific and clinical research across its diverse oncology portfolio and pipeline, featuring data in hard-to-treat tumor types like non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and small cell lung cancer (SCLC).

“Our presentations at ASCO… illustrate how we’re advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen. “We’re focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer.”  

Highlights from Amgen’s presentations included data on LUMAKRAS® (sotorasib) from the first study evaluating its intracranial efficacy as a KRAS G12C inhibitor versus docetaxel in treated KRAS G12C-mutated advanced NSCLC. Additional analyses from DeLLphi-300 highlighted the safety and clinical efficacy of Tarlatamab, an investigational first-in-class BiTE® immunotherapy, in patients with SCLC with treated and stable brain metastases. Other studies presented novel combinations showing encouraging safety and efficacy in pre-treated KRAS G12C-mutated metastatic CRC and first-line NSCLC.

These presentations showed advances in several therapeutic areas, including hematologic malignancies, melanoma/skin cancers, and gastrointestinal cancers. Some of the key clinical studies presented include the IKEMA study for KYPROLIS®, the PARADIGM trial for VECTIBIX®, and a phase 2 study on IMLYGIC® in advanced sarcoma.

One company also potentially (yet indirectly) making significant strides in the oncology sector is Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a Newark, California-based biopharmaceutical firm. Although not traditionally labeled as a cancer biotech firm, their innovative approach towards blood disorders, notably Polycythemia Vera, a slow-growing blood cancer, underscores their contribution to the broader oncology landscape.

Protagonist’s leading drug candidate, rusfertide (PTG-300), is currently under the microscope. The company recently announced that additional data from the REVIVE study of rusfertide in polycythemia vera would be presented at the annual Congress of the European Hematology Association (EHA). This study holds immense promise as it explores the ability of rusfertide to improve symptoms related to this blood disorder.

The Moffitt Cancer Center and the Department of Malignant Hematology have taken a keen interest in this study, suggesting rusfertide’s potential broader application in the field of hematology and possibly in other forms of cancer. An assistant member of the Department, Dr. Andrew Kuykendall, will present the study results, further demonstrating the deep links between Protagonist’s work and oncology professionals.

Moreover, Protagonist is also advancing their peptide-based new chemical entity, JNJ-2113 (formerly PN-235), which recently showed positive topline results in treating moderate-to-severe plaque psoriasis. While psoriasis is not a form of cancer, the advancement of these biological drugs signals a new direction in treating various human conditions, including cancers.

Article Source: 

Article Source:
USA News Group 
[email protected]

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:  
[email protected] 
U.S. Phone: +1(954)345-0611

View original content:

Continue Reading

Latest news